Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2007 by Children's Hospital Boston.
Recruitment status was  Active, not recruiting
Progeria Research Foundation
Information provided by:
Children's Hospital Boston Identifier:
First received: January 22, 2007
Last updated: December 24, 2007
Last verified: December 2007